Dublin, March 16, 2021 (GLOBE NEWSWIRE) -- The "Dermatology Drugs Market Research Report: By Treatment, Drug, Prescription Mode, Therapy Area, Distribution Channel, End User - Global Industry Analysis and Growth Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
The market is predicted to advance at the CAGR of 8.2% during the forecast period, from its recorded value of $21.5 billion in 2017, to reach $34.5 billion by 2023.
Due to the rise in the geriatric population, growing prevalence of dermatological diseases, increasing awareness about skin problems, soaring spending capability of the people, and huge pipeline of dermatological drugs, the global dermatology drugs market is expected to advance rapidly during the forecast period (2018-2023).
The increasing prevalence of skin diseases is one of the biggest factors boosting the growth of the dermatology drugs market. Trauma, environmental and genetic factors, and aging are some of the most significant factors causing skin diseases in millions of people across the globe. As per the observations of the World Health Organization (WHO), skin diseases are one of the most common forms of health disorders and they affect nearly 900 million people at a time, around the world.
With the increase in age, the proper functioning of the human skin starts to be lost, resulting in the occurrence of various skin diseases, thereby driving the progress of the dermatology drugs market. Moreover, with age, the body also starts experiencing several other problems, such as slow healing of wounds, higher sensitivity to ultraviolet (UV) radiation, greater vulnerability to infections, and reduction in subcutaneous fat. This increases the probability of various skin problems, thereby shooting up the demand for dermatological drugs.
Based on treatment, the dermatology drugs market is divided into multiple categories, namely retinoids, calcineurin inhibitors, hormonal therapy, topical corticosteroids, biologics, antihistamines, and others, wherein the others category includes antifungal, antibacterial, and antiviral agents and enzyme inhibitors.
Amongst the different categories, topical corticosteroids had the largest share in the market, in terms of revenue, in 2017. This was primarily due to the rise in the demand for these drugs as a result of the growing prevalence of eczema across the world.
Key Topics Covered:
Chapter 1. Research Background
Chapter 2. Research Methodology
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1 Definition of Market Segments
4.1.1 By Treatment
4.1.1.1 Topical corticosteroids
4.1.1.2 Retinoids
4.1.1.3 Biologics
4.1.1.4 Calcineurin inhibitors
4.1.1.5 Antihistamines
4.1.1.6 Hormone therapy
4.1.1.7 Others
4.1.2 By Drug
4.1.2.1 Humira
4.1.2.2 Remicade
4.1.2.3 Otezla
4.1.2.4 Stelara
4.1.2.5 Enbrel
4.1.2.6 Cosentyx
4.1.2.7 Neoral
4.1.2.8 Taltz
4.1.2.9 Cubicin
4.1.2.10 Canesten
4.1.2.11 Zyvox
4.1.2.12 Dupixent
4.1.2.13 Protopic
4.1.2.14 Valtrex
4.1.2.15 Eucrisa
4.1.2.16 Others
4.1.3 By Prescription Mode
4.1.3.1 Prescription drugs
4.1.3.2 OTC drugs
4.1.4 By Therapeutic Area
4.1.4.1 Psoriasis
4.1.4.2 Atopic dermatitis
4.1.4.3 Acne
4.1.4.4 Rosacea
4.1.4.5 Skin cancer
4.1.4.6 Scar
4.1.4.7 Others
4.1.5 By Distribution Channel
4.1.5.1 Direct
4.1.5.2 Wholesale/retail
4.1.5.3 Online
4.1.6 By End User
4.1.6.1 Hospitals
4.1.6.2 Clinics
4.1.6.3 Cosmetic centers
4.1.6.4 At-home
4.1.6.5 Others
4.2 Market Dynamics
4.2.1 Trends
4.2.1.1 Product approvals
4.2.2 Drivers
4.2.2.1 Rising geriatric population
4.2.2.2 Increasing incidence of dermatological diseases
4.2.2.3 Growing awareness on skin diseases
4.2.2.4 Increasing personal care spending
4.2.2.5 Strong pipeline of dermatological drugs
4.2.2.6 Impact analysis of drivers on market forecast
4.2.3 Restraints
4.2.3.1 Patent expiry and generic drug development
4.2.3.2 Side-effects of certain classes of therapeutic drugs
4.2.3.3 Impact analysis of restraints on market forecast
4.2.4 Opportunities
4.2.4.1 Huge potential in emerging markets
4.3 Impact of COVID-19
4.4 Porter's Five Forces Analysis
Chapter 5. Global Market Size and Forecast
5.1 Overview
5.2 By Treatment
5.3 By Drug
5.4 By Prescription Mode
5.5 By Therapy Area
5.5.1 Psoriasis Drugs Market, by Prescription Mode
5.5.2 Atopic Dermatitis Drugs Market, by Prescription Mode
5.5.3 Acne Drugs Market, by Prescription Mode
5.5.4 Rosacea Drugs Market, by Prescription Mode
5.5.5 Scar Drugs Market, by Prescription Mode
5.5.6 Skin Cancer Drugs Market, by Prescription Mode
5.6 By Distribution Channel
5.7 By End User
5.8 By Region
Chapter 6. North America Market Size and Forecast
Chapter 7. Europe Market Size and Forecast
Chapter 8. APAC Market Size and Forecast
Chapter 9. LATAM Market Size and Forecast
Chapter 10. MEA Market Size and Forecast
Chapter 11. Competitive Landscape
11.1 Product Benchmarking of Key Players
11.2 Strategic Developments
11.2.1 Product Launches and Approvals
11.2.2 Acquisitions
11.2.3 Other Developments
Chapter 12. Company Profiles
- Bausch Health Companies Inc.
- Novartis AG
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Johnson & Johnson
- Merck & Co. Inc.
- Amgen Inc.
- AbbVie Inc.
- Eli Lilly and Company
- Galderma S.A.
- GlaxoSmithKline plc
- Mylan N.V.
- LEO Pharma A/S
- Sanofi
For more information about this report visit https://www.researchandmarkets.com/r/cexq6